BioMarin Pharmaceutical Inc. (BMRN) financial statements (2022 and earlier)

Company profile

Business Address 105 DIGITAL DRIVE
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,0141,0657541,0841,396790593
Cash and cash equivalents587649437494598408397
Short-term investments427416316590798381196
Receivables373448377343261215165
Inventory, net of allowances, customer advances and progress billings777699680531476355272
Inventory777699680531476355272
Other current assets11013013198746260
Total current assets:2,2742,3421,9422,0562,2071,4221,090
Noncurrent Assets
Property, plant and equipment1,0351,0321,011949897799704
Long-term investments and receivables508285412236386573426
Long-term investments508285412236386573426
Intangible assets, net (including goodwill)585613654689715751881
Goodwill196196197197197197197
Intangible assets, net (excluding goodwill)389417457492518554684
Deferred income tax assets1,4491,432549
Other noncurrent assets152142122373033409
Other undisclosed noncurrent assets   461399447220
Total noncurrent assets:3,7293,5062,7482,3712,4262,6022,640
TOTAL ASSETS:6,0035,8484,6904,4274,6334,0243,729
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:492493571437402371393
Accrued liabilities15173163555043
Employee-related liabilities20416519215014110978
Taxes payable210881086
Other undisclosed accounts payable and accrued liabilities270301339216196204265
Debt  362 36122 
Business combination, contingent consideration, liability48  86544653
Total current liabilities:540493933523817439445
Noncurrent Liabilities
Long-term debt and lease obligation1,0791,075486830814661662
Long-term debt, excluding current maturities1,0791,075486830814661662
Liabilities, other than long-term debt114174149106194157221
Deferred tax liabilities, net   144
Other liabilities991149859594245
Business combination, contingent consideration, liability1560514713511533
Total noncurrent liabilities:1,1931,2496359361,008818883
Total liabilities:1,7331,7421,5681,4591,8241,2571,329
Stockholders' equity
Stockholders' equity attributable to parent, including:4,2714,1063,1222,9682,8092,7662,401
Common stock0000000
Additional paid in capital5,1924,9934,8334,6704,4834,2883,415
Accumulated other comprehensive income (loss)14(16)205(23)1321
Accumulated deficit(926)(862)(1,721)(1,694)(1,638)(1,521)(1,022)
Other undisclosed stockholders' equity attributable to parent(10)(10)(10)(13)(14)(14)(14)
Total stockholders' equity:4,2714,1063,1222,9682,8092,7662,401
TOTAL LIABILITIES AND EQUITY:6,0035,8484,6904,4274,6334,0243,729

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1,8461,8601,7041,4911,3141,117890
Revenue, net1,3141,117890
Cost of revenue(471)(524)(359)(315)(242)(210)(152)
Gross profit:1,3761,3361,3451,1761,072907738
Operating expenses(1,388)(1,306)(1,371)(1,251)(1,040)(1,138)(668)
Other undisclosed operating loss(70)(67)(74)(49)(46)(572)(181)
Operating loss:(82)(37)(100)(124)(15)(803)(111)
Nonoperating income109224192224
Investment income, nonoperating101723231575
Foreign currency transaction gain (loss), before tax (8)(1)18(6)1420
Interest and debt expense(15)(29)(23)(44)(43)(39)(38)
Loss from continuing operations before equity method investments, income taxes:(87)(57)(102)(127)(49)(821)(125)
Loss from equity method investments (0)(1)(1)(1)(1)(1)
Other undisclosed income (loss) from continuing operations before income taxes12158(16)14(10)(29)
Loss from continuing operations before income taxes:(75)(42)(95)(143)(36)(831)(155)
Income tax expense (benefit)119017165(81)201(17)
Net income (loss) available to common stockholders, basic:(64)859(24)(77)(117)(630)(172)
Interest on convertible debt 8     
Other undisclosed net loss available to common stockholders, diluted   (1) (3) 
Net income (loss) available to common stockholders, diluted:(64)867(24)(78)(117)(633)(172)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(64)859(24)(77)(117)(630)(172)
Other comprehensive income (loss)31(36)1529(36)(8)(6)
Comprehensive income (loss), net of tax, attributable to parent:(34)823(9)(48)(153)(638)(178)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: